U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Niagen Bioscience

Market Cap: US$791.2m

Operates as a bioscience company engages in developing healthy aging products.

Ligand Pharmaceuticals

Market Cap: US$3.2b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

BioLife Solutions

Market Cap: US$1.2b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Rhythm Pharmaceuticals

Market Cap: US$6.9b

A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.

Eli Lilly

Market Cap: US$657.7b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

Sotera Health

Market Cap: US$4.6b

Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.

Repligen

Market Cap: US$6.9b

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Caris Life Sciences

Market Cap: US$10.8b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Alnylam Pharmaceuticals

Market Cap: US$58.5b

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

Natera

Market Cap: US$23.1b

A diagnostics company, provides molecular testing services worldwide.